1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Phenytoin Sodium Capsules (100 and 300mg)

Trade Name: Dilantin; Epanutin; Epamin

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for seizures and epilepsy.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4
Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2

Label Elements

Signal Word: Danger

Hazard Statements:
H302 - Harmful if swallowed
H351 - Suspected of causing cancer
H360D - May damage the unborn child

Precautionary Statements:
P202 - Do not handle until all safety precautions have been read and understood
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P281 - Use personal protective equipment as required
P301+P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P330 - Rinse mouth
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards
Note: No data available
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin Sodium</td>
<td>630-93-3</td>
<td>211-148-2</td>
<td>Acute Tox. 4 (H302) Carc. 2 (H351) Repr. 1B (H360D)</td>
<td>80</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silica colloidal, Ph. Eur.</td>
<td>112945-52-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

Description of First Aid Measures

**Eye Contact:** Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

**Skin Contact:** Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

**Inhalation:** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

**Most Important Symptoms and Effects, Both Acute and Delayed Symptoms and Effects of Exposure:** No data available
5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: No data available
Fire / Explosion Hazards: No data available

Advice for Fire-Fighters
Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Phenytoin Sodium
Pfizer OEL TWA-8 Hr: 400 µg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Material Name: Phenytoin Sodium Capsules (100 and 300mg)

Color: Green

Odor: No data available.

Molecular Formula: Mixture

Molecular Weight: Mixture

Solvent Solubility: No data available

Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available

Partition Coefficient: (Method, pH, Endpoint, Value)

Phenytoin Predicted 7.4 Log D 2.47

Phenytoin Sodium No data available

Magnesium Stearate No data available

Lactose No data available

Silica colloidal, Ph. Eur. No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: No data available
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information in this section describes the hazards of various forms of the active ingredient. The remaining information describes the potential hazards of the individual ingredients.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, gastrointestinal system and liver.
Known Clinical Effects: The most common adverse effects observed with clinical use of phenytoin are lack of appetite, headache, dizziness, transient nervousness, ataxia, slurred speech, decreased coordination, mental confusion, insomnia, and GI disturbances (nausea, vomiting, and constipation). IV administration has been associated with hypotension and CNS depression. Mild hypersensitivity reactions (skin rashes) are common. Effects on blood-forming organs and the liver have occurred rarely. Other less common effects include swollen lymph nodes, sore mouth and symptoms of dependence/withdrawal. There is an unconfirmed association between the use of anticonvulsants during pregnancy and an increased risk of birth defects. This material has been shown to be secreted in low concentrations in human breast milk.

Acute Toxicity: (Species, Route, End Point, Dose)

Phenytoin
Mouse Oral LD50 150 mg/kg
Rat Oral LD50 1635mg/kg
Rat Intravenous LD 50 96mg/kg
Rat IM LD 50 >337mg/kg
Rabbit Oral LD 50 >3000mg/kg

Phenytoin Sodium
Mouse Oral LD50 165 mg/kg
Rat Oral LD50 1530mg/kg
Rat IV LD50 90mg/kg
Mouse IV LD 50 98mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Phenytoin
2 Week(s)  Rat  Oral  <3125 ppm/day  NOEL  Bone marrow
2 Week(s)  Mouse  Oral  <125 ppm/day  NOEL  Central Nervous System
13 Week(s)  Rat  Oral  300 ppm/day  NOEL  None identified
13 Week(s)  Mouse  Oral  150 ppm/day  NOEL  Blood forming organs, Gastrointestinal system, Liver

Magnesium Stearate
13 Week(s)  Rat  Oral  1092 g/kg  LOAEL  Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Phenytoin
Embryo / Fetal Development  Mouse  Oral  75 mg/kg/day  NOEL  Maternal toxicity, Fetotoxicity, Teratogenic
Embryo / Fetal Development  Mouse  Oral  45 mg/kg/day  NOEL  Teratogenic
Embryo / Fetal Development  Rabbit  Oral  50 mg/kg/day  NOEL  Fetotoxicity, Teratogenic
Embryo / Fetal Development  Monkey  Oral  10 mg/kg/day  NOEL  Fetotoxicity, Teratogenic
Embryo / Fetal Development  Mouse  Subcutaneous  <12.5 mg/kg/day  NOEL  Maternal Toxicity, Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Phenytoin
Bacterial Mutagenicity (Ames)  Salmonella  Negative
In Vitro Chromosome Aberration  Chinese Hamster Ovary (CHO) cells  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative
In Vivo Sister Chromatid Exchange  Human Lymphocytes  Positive
In Vivo Mitotic Spindle Assay  Human Lymphocytes  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Phenytoin
2 Year(s)  Male Rat  Oral, in feed  50 mg/kg/day  NOEL  Benign neoplasms, Skin
2 Year(s)  Mouse  Oral, in feed  25 mg/kg/day  NOEL  Benign tumors, Liver
2 Year(s)  Female Mouse  Oral, in feed  60 ppm  LOAEL  Liver, neoplasms
2 Year(s)  Female Rat  Oral, in feed  240 ppm  NOAEL  Not carcinogenic

Carcinogen Status:

Phenytoin
IARC:  Group 2B (Possibly Carcinogenic to Humans)
NTP:  Reasonably Anticipated To Be A Human Carcinogen

Phenytoin Sodium
IARC:  Group 2B (Possibly Carcinogenic to Humans)
NTP:  Reasonably Anticipated To Be A Human Carcinogen

Silica colloidal, Ph. Eur.
IARC:  Group 3 (Not Classifiable)
12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See aquatic toxicity data, below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Phenytoin
Hyallela azteca (Freshwater Amphipod) OPPTS LC50 96 Hours 18 mg/L
Daphnia magna (Water Flea) TAD EC50 48 Hours >39 mg/L
Pimephales promelas (Fathead Minnow) OPPTS LC50 96 Hours >23 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Phenytoin
Predicted 7.4 Log D 2.47

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture
15. REGULATORY INFORMATION

Phenytoin Sodium

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Carcinogen initial date 1/1/88
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 211-148-2

Silica colloidal, Ph. Eur.

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Australia (AICS): Present
EU EINECS/ELINCS List: Not Listed

Lactose

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List: 200-559-2

Magnesium Stearate

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 209-150-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 16-May-2016

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.
End of Safety Data Sheet